Published at LXer: There are lots of other advantages of running a full, static HTML website. We pick the finest Awk-based tools. Read More......

Prevent Static Electricity from damaging your delicate computer components

Is web hosting with dedicated (static) IP address better than having a shared IP address for your website? Due to the rapid increase of the number of registered domain names and the finite number of IP addresses, web hosting providers are forced to use shared IP's when possible. In fact, hundreds of websites often share the same address. Dedicated IP hosting is no longer the norm and usually costs more.

Nearly a third of charity chief executives have experienced discrimination or barriers during their career in the sector, Acevo says

The Ion Air Cannon eliminates static electricity and cleans at distances up to 15 feet, with no moving parts.

When the static electricity in a medical office, examination room or lab is under control, it helps reduce the risks of shocks to personnel, disruption of data, malfunction of sensitive equipment, igniting flammables, and reducing contamination due to electrostatic attraction.

Imaging energy filters in photoelectron microscopes and momentum microscopes use spherical fields with deflection angles of 90°, 180° and even 2 × 180°. These instruments are optimized for high energy resolution, and exhibit image aberrations when operated in high transmission mode at medium energy resolution. Here, a new approach is presented for bandpass-filtered imaging in real or reciprocal space using an electrostatic dodecapole with an asymmetric electrode array. In addition to energy-dispersive beam deflection, this multipole allows aberration correction up to the third order. Here, its use is described as a bandpass prefilter in a time-of-flight momentum microscope at the hard X-ray beamline P22 of PETRA III. The entire instrument is housed in a straight vacuum tube because the deflection angle is only 4° and the beam displacement in the filter is only ∼8 mm. The multipole is framed by transfer lenses in the entrance and exit branches. Two sets of 16 different-sized entrance and exit apertures on piezomotor-driven mounts allow selection of the desired bandpass. For pass energies between 100 and 1400 eV and slit widths between 0.5 and 4 mm, the transmitted kinetic energy intervals are between 10 eV and a few hundred electronvolts (full width at half-maximum). The filter eliminates all higher or lower energy signals outside the selected bandpass, significantly improving the signal-to-background ratio in the time-of-flight analyzer.

Webstone, a brand of NIBCO, introduces the new Thermostatic Mixing Valve for high-temperature solar heat sources.

Haro-Lund introduces a new static mixing technology, which combines significantly better mixing, with an order of magnitude reduction in costs compared to the industry standard helical element by utilizing die cutting equipment for manufacturing.

By Gerald E. Ulen Discover the Hidden Realms of Electricity with Gerald E. Ulen's Upcoming Release

With Mango Animate's talking avatar AI tool, users can effortlessly animate photos to express thoughts and emotions. This tool makes digital communication more dynamic and engaging.

The premium cloud hosting provider adds static site hosting to its services, which also include WordPress, application, and database hosting

RSS is a classic technology that fetches content from websites and feeds it to anyone who subscribes to it with a URL. It’s based on XML, and we can use it to consume the feeds in our own apps. Karin Hendrikse demonstrates how to do exactly that with a static site you can use as your personal RSS reader.

This article will hopefully save the lives of a few TXVs and the pocketbooks of some customers.

As the old saying goes, an ounce of prevention is worth a pound of cure. This is especially true when a replacing a thermostatic expansion valve (TXV).

Implementing company-wide static pressure measurements can be tough. Let’s look at how you can use red flags to improve your static pressure measurement consistency and reduce callbacks.

Is it time for our industry to consider using pascals for static pressure measurements? What would the transition from inches of water column to pascals look like and how hard would it be?

In this Episode we talk about dynamic languages for statically-typed minds, or in other words: which are the interesting features people should learn when they go from a langauge such as Java or C# to a language like Python or Ruby. We used Ruby as the concrete example language.

We started the discussion about important features with the concept of dynamically changing an object's type and the idea of message passing. We then looked at the concepts of blocks and closures. Next in line is a discussion about functions that create functions as well as currying. This lead into a quick discussion about continuations. Open classes, aliasing and the relationship to AOP was next on our agenda.

We then looked considered a somewhat more engineering-oriented view and looked at the importance of testing and what are the best steps of getting from static programming to dynamic programming. Finally, we discussed a bit about the current (as of October 2006) state of dynamic languages on mainstream platforms.

This episode is a discussion with Jonathan Aldrich (Assistant Professor at CMU) about static analysis. The discussion covered theory as well as practice and tools. We started with an explanation of what static analysis actually is, which kinds of errors it can find and how it is different from testing and reviews. The core challenge of such an analysis tool is to understand the semantics of the program and reduce its possible state space to make it analysable - in effect reconstructing the programmer's intent from the code. The user can "help" the tool with this challenge by using suitable annotations; also, languages could do a better job of being analysable. The conceptual discussion was concluded by looking at the principles of static analysis (termination, soundness. precision) and how this approach relates to model analysis. The second more practical part started out with a discussion of how Microsoft successfully uses static analysis in their Windows development. We then discussed some of the tools available; these include Findbugs, Coverity, Codesonar, Clockwork, Fortify, Polyspace and Codesurfer. To conclude the discussion of tools, we discussed the commonalities and differences with architecture visualization tools as well as metrics and heuristics. Part three of the discussion briefly looked at how to introduce static analysis tools into an organization's development process and tool chain. We concluded the discussion by looking at situations where static analysis does not work, as well as at the FLUID research project at CMU.

All of the QR (Quick Response) codes that I have created are static QR codes which served one function and that was to take you to a certain website.

QR codes have definitely evolved over time so take a look at the article from Edutopia entitled QR Codes Can Do That? and find out how to:

• Add your voice
• Attach PDF files
• Collect information
• Send a tweet
• Change locations

Choosing the power of a static UPS system serving a data center is a decision that involves various elements and which cannot be made before, or independently from, the choice of distribution scheme. The main elements to consider can be summarised... Read more

The post Sizing a Static UPS System In Data Center appeared first on EEP - Electrical Engineering Portal.

Let’s start with basics you probably already know, but nevertheless. It’s important to explain the basics first. Electrostatic Discharge (or ESD) refers to the transfer of electrostatic charge between bodies at varied voltages that is caused by direct contact or... Read more

The post Never underestimate electrostatic discharge (ESD) while working with data networking equipment appeared first on EEP - Electrical Engineering Portal.

The DTY-ELF14HC Multi-Function, Self-Cleaning Ionizer is designed for easy and efficient static electricity removal.

Specification and Description Language - Overview of SDL-2010 - SDL-2010 formal definition: Static semantics

Specification and Description Language - Overview of SDL-2010 - SDL formal definition: Static semantics

Radio Static is a small and ultimately pointless internet radio that plays nothing but various forms of static and occasionally some industrial noises that also kind of sound like static (can also be downloaded here for offline play).

[Link

Visual Abstract

Visual Abstract

Visual Abstract

Visual Abstract

The extracellular matrix encompasses a reservoir of bioactive macromolecules that modulates a cornucopia of biological functions. A prominent body of work posits matrix constituents as master regulators of autophagy and angiogenesis and provides molecular insight into how these two processes are coordinated. Here, we review current understanding of the molecular mechanisms underlying hyaluronan and HAS2 regulation and the role of soluble proteoglycan in affecting autophagy and angiogenesis. Specifically, we assess the role of proteoglycan-evoked autophagy in regulating angiogenesis via the HAS2-hyaluronan axis and ATG9A, a novel HAS2 binding partner. We discuss extracellular hyaluronan biology and the post-transcriptional and post-translational modifications that regulate its main synthesizer, HAS2. We highlight the emerging group of proteoglycans that utilize outside-in signaling to modulate autophagy and angiogenesis in cancer microenvironments and thoroughly review the most up-to-date understanding of endorepellin signaling in vascular endothelia, providing insight into the temporal complexities involved.

Understanding which patients with human epidermal growth factor receptor 2 (HER2)–negative or –low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is urgently needed. We assessed the whole-body heterogeneity of HER2 expression on ⁸⁹Zr-trastuzumab PET (HER2 PET) and the diagnostic performance of HER2 PET in a large series of patients, including HER2-negative and -low MBC. Methods: In the IMPACT-MBC study, patients with newly diagnosed and nonrapidly progressive MBC of all subtypes were included. Metastasis HER2 status was determined by immunohistochemistry and in situ hybridization.⁸⁹Zr-trastuzumab uptake was quantified as SUV_max and SUV_mean. HER2 immunohistochemistry was related to the quantitative ⁸⁹Zr-trastuzumab uptake of all metastases and corresponding biopsied metastasis, uptake heterogeneity, and qualitative scan evaluation. A prediction algorithm for HER2 immunohistochemistry positivity based on uptake was developed. Results: In 200 patients, ⁸⁹Zr-trastuzumab uptake was quantified in 5,163 metastases, including 186 biopsied metastases. With increasing HER2 immunohistochemistry status, uptake was higher (geometric mean SUV_max of 7.0, 7.6, 7.3, and 17.4 for a HER2 immunohistochemistry score of 0, 1, 2, or 3+, respectively; P < 0.001). High uptake exceeding 14.6 (90th percentile) was observed in one third of patients with a HER2-negative or -low metastasis biopsy. The algorithm performed best when lesion site and size were incorporated (area under the curve, 0.86; 95% CI, 0.79–0.93). Conclusion: HER2 PET had good diagnostic performance in MBC, showing considerable whole-body HER2 heterogeneity and uptake above background in HER2-negative and -low MBC. This provides novel insights into HER2-negative and -low MBC compared with standard HER2 immunohistochemistry on a single biopsy.

William W. Seeley
Dec 11, 2019; 39:9878-9882
Progressions

Neural reflexes occupy a central role in physiological homeostasis. The vagus nerve is a major conduit for transmitting afferent and efferent signals in homeostatic reflex arcs between the body and the brain. Recent advances in neuroscience, immunology, and physiology have revealed important vagus nerve mechanisms in suppressing inflammation and treating rheumatoid arthritis and other autoimmune conditions. Numerous clinical trials indicate that there is significant benefit to vagus nerve stimulation therapy. Although many questions are still unanswered, it will be important, even necessary, to pursue answers that will be useful in guiding interventions to modulate immunological and physiological homeostasis.

The phase 3 VISION trial demonstrated that [¹⁷⁷Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]–positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor–signaling inhibitors (ARSIs). The U.S. expanded-access program (EAP; NCT04825652) was opened to provide access to [¹⁷⁷Lu]Lu-PSMA-617 for eligible patients until regulatory approval was obtained. This study aimed to evaluate the efficacy and safety profile of [¹⁷⁷Lu]Lu-PSMA-617 within the EAP and compare the results with those from the VISION trial. Methods: Patients enrolled in the EAP at 4 institutions in the United States with available toxicity and outcome data were included. Outcome measures included OS, a prostate-specific antigen (PSA) response rate (RR) of at least 50%, and incidences of toxicity according to Common Terminology Criteria for Adverse Events version 5.0. Differences in baseline characteristics, outcome data, and toxicity between the EAP and VISION were evaluated using t testing of proportions and survival analyses. Results: In total, 117 patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP between May 2021 and March 2022 were eligible and included in this analysis. Patients enrolled in the EAP were more heavily pretreated with ARSI (≥2 ARSI regimens: 70% vs. 46%; P < 0.001) and had worse performance status at baseline (Eastern Cooperative Oncology Group score ≥ 2: 19% vs. 7%; P < 0.001) than VISION patients. EAP and VISION patients had similar levels of grade 3 or higher anemia (18% vs. 13%; P = 0.15), thrombocytopenia (13% vs. 8%; P = 0.13), and neutropenia (3% vs. 3%; P = 0.85) and similar PSA RRs (42% vs. 46%; P = 0.50) and OS (median: 15.1 vs. 15.3 mo; P > 0.05). Conclusion: Patients with PSMA-positive mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP were later in their disease trajectory than VISION patients. Patients enrolled in the EAP achieved similar PSA RRs and OS and had a safety profile similar to that of the VISION trial patients.

[¹⁷⁷Lu]Lu-PSMA-617 was approved by the U.S. Food and Drug Administration for patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC). Since the time of regulatory approval, however, real-world data have been lacking. This study investigated the efficacy, safety, and outcome predictors of [¹⁷⁷Lu]Lu-PSMA-617 at a major U.S. academic center. Methods: Patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 at the Johns Hopkins Hospital outside clinical trials were screened for inclusion. Patients who underwent [¹⁷⁷Lu]Lu-PSMA-617 and had available outcome data were included in this study. Outcome data included prostate-specific antigen (PSA) response (≥50% decline), PSA progression-free survival (PFS), and overall survival (OS). Toxicity data were evaluated according to the Common Terminology Criteria for Adverse Events version 5.03. The study tested the association of baseline circulating tumor DNA mutational status in homologous recombination repair, PI3K alteration pathway, and aggressive-variant prostate cancer–associated genes with treatment outcome. Baseline PSMA PET/CT images were analyzed using SelectPSMA, an artificial intelligence algorithm, to predict treatment outcome. Associations with the observed treatment outcome were evaluated. Results: All 76 patients with PSMA-positive mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 met the inclusion criteria. A PSA response was achieved in 30 of 74 (41%) patients. The median PSA PFS was 4.1 mo (95% CI, 2.0–6.2 mo), and the median OS was 13.7 mo (95% CI, 11.3–16.1 mo). Anemia of grade 3 or greater, thrombocytopenia, and neutropenia were observed in 9 (12%), 3 (4%), and 1 (1%), respectively, of 76 patients. Transient xerostomia was observed in 23 (28%) patients. The presence of aggressive-variant prostate cancer–associated genes was associated with a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P = 0.040). No other associations were observed between circulating tumor DNA mutational status and treatment outcomes. Eighteen of 71 (25%) patients classified by SelectPSMA as nonresponders had significantly lower rates of PSA response than patients classified as likely responders (6% vs. 51%; P < 0.001), a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P < 0.001), and a shorter OS (median, 6.3 vs. 14.5 mo; P = 0.046). Conclusion: [¹⁷⁷Lu]Lu-PSMA-617 offered in a real-world setting after regulatory approval in the United States demonstrated antitumor activity and a favorable toxicity profile. Artificial-intelligence–based analysis of baseline PSMA PET/CT images may improve patient selection. Validation of these findings on larger cohorts is warranted.

Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. Methods: This was a multisite prospective observational study in which mCRPC patients underwent both ¹⁸F-FDG and ⁶⁸Ga-prostate-specific membrane antigen (PSMA)–617 PET/CT scans. A third scan with ⁶⁸Ga-DOTATATE, a potential biomarker of neuroendocrine differentiation, was performed if an ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found. Per-tracer lesion positivity was defined as having an uptake at least 50% above that of the liver. IIH prevalence was defined as the percentage of participants having at least 2 lesions with discordant features on multitracer PET. Results: IIH was observed in 81 patients (82.7%), and at least 1 ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found in 45 patients (45.9%). Of the 37 participants who also underwent ⁶⁸Ga-DOTATATE PET/CT, 6 (16.2%) had at least 1 ⁶⁸Ga-DOTATATE–positive lesion. In total, 12 different combinations of lesion imaging phenotypes were observed. On the basis of our prespecified criteria, 52 (53.1%) participants were determined to be eligible for PSMA RPT, but none for DOTATATE RPT. Patients with IIH had a significantly shorter median overall survival than patients without IIH (9.5 mo vs. not reached; log-rank P = 0.03; hazard ratio, 2.7; 95% CI, 1.1–6.8). Conclusion: Most mCRPC patients showed IIH, which was associated with shorter overall survival. On the basis of a triple-tracer PET approach, multiple phenotypic combinations were found. Correlation of these imaging phenotypes with genomics and treatment response will be relevant for precision medicine.

The clinical impact of 16α-¹⁸F-fluoro-17β-estradiol (¹⁸F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of ¹⁸F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer. Methods: Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of ¹⁸F-FES between 2021 and 2023. Patients who were suspected or known to have recurrent or metastatic estrogen receptor–positive breast cancer based on a routine standard workup were included. Planned management before and actual management after ¹⁸F-FES PET/CT were assessed by 2 experienced medical oncologists via medical chart review. A 5-point questionnaire was provided to evaluate the value of ¹⁸F-FES PET/CT for management planning. The rate of intention-to-treat and interdisciplinary changes, and the impact of ¹⁸F-FES PET/CT according to PET/CT result or clinical indication, were examined. Results: Of the 344 included patients, 120 (35%) experienced a change in management after ¹⁸F-FES PET/CT. In 139 (40%) patients,¹⁸F-FES PET/CT supported the existing management decision without a change in management. Intention-to-treat and interdisciplinary changes accounted for 64% (77/120) and 68% (82/120) of all changes, respectively. A higher rate of change was observed when lesions were ¹⁸F-FES–negative (44% [36/81]) than ¹⁸F-FES–positive (30% [51/172]) or mixed ¹⁸F-FES–positive/negative (36% [33/91]). Regarding clinical indications, the highest rate of change was shown when evaluating the origins of metastasis of double primary cancers (64% [9/14]). Conclusion: ¹⁸F-FES PET/CT modified the management of recurrent or metastatic breast cancer, serving as an impactful imaging modality in clinical practice.

Metastatic porocarcinomas (PCs) are vanishingly rare, highly aggressive skin adnexal tumors with mortality rates exceeding 70%. Their rarity has precluded the understanding of their disease pathogenesis, let alone the conduct of clinical trials to evaluate treatment strategies. There are no effective agents for unresectable PCs. Here, we successfully demonstrate how functional precision medicine was implemented in the clinic for a metastatic PC with no known systemic treatment options. Comprehensive genomic profiling of the tumor specimen did not yield any actionable genomic aberrations. However, ex vivo drug testing predicted pazopanib efficacy, and indeed, administration of pazopanib elicited remarkable clinicoradiological response. Pazopanib and its class of drugs should be evaluated for efficacy in other cases of PC, and the rationale for efficacy should be determined when PC tumor models become available. A functional precision medicine approach could be useful to derive effective treatment options for rare cancers.

SOLARIS, a phase 3 clinical trial led by Dana-Farber Cancer Institute, tested the addition of high-dose medlinkvitamin D3/medlink to standard treatment

medlinkColorectal cancer/medlink frequently metastasizes to the liver, and for some patients, surgical removal of liver tumors is not feasible. A

Dual treatment has improved the survival rates for men with metastatic prostate cancer by an average of six months. Dual treatment includes both standard

One of the generic Indian pharmaceutical companies, Hetero Drugs has launched a biosimilar for the treatment of metastatic colorectal cancer (mCRC) in India.